Abstract:The recent development of artificial intelligence (AI) technology is bringing about changes at a faster pace and on a larger scale than any other period in human history. With technological advancements overcoming the limitations of medical AI through training with databases, AI technology has made remarkable progress since the inception of deep learning for image processing with convolutional neural networks (CNN) in 2012. The recent advancements in natural language processing (NLP) have accelerated the utilization of AI through sophisticated natural language processing, enabling machines to identify and understand data regardless of the complexity of the language. This has laid the foundation for the rapid and precise development of generative AI. In the era where generative AI is being utilized without pausing in its developmental speed, we considered the civil liability of AI in our civil law principles, taking into account the inherent characteristics of AI such as unpredictability, opacity, and the black box effect. To do this, we first examined the legal liability considering the stages of AI technology development in discussing the tort liability caused by AI. Even “Weak AI,” created by AI developers, may fall under “Gefahr,” and while not all types, some may apply to strict liability in terms of risk liability. Furthermore, while reviewing civil liability applicable to AI under fault-based and no-fault liability, we also looked at the trends in the EU comparatively. In discussing no-fault liability, particularly under the Product Liability Act, we examined the possibility and implications of applying risk liability to pharmaceutical manufacturing using generative AI technology as a representative example to overcome the limitations of the existing Product Liability Act. Humanity currently lives in an era of rapid technological development and exploding big data, enjoying numerous benefits due to these advancements. As user convenience improves and massive added value is created through technological progress, the meaning of risk liability in the realm of civil liability can gain more significance. Generative AI has already drastically reduced the costs and time required for new drug development, providing substantial profits to pharmaceutical companies. However, even if the existing Product Liability Act is applied, it may be difficult to adequately remedy the harm to victims due to the reasonable alternative possibility defense regarding design defects. In the era of generative AI, we examined the possibility of applying enhanced risk liability by assuming the case of pharmaceutical manufacturing.

Exploring remedies for defective artificial intelligence aids in clinical decision-making in post-Brexit England and Wales

Artificial intelligence in clinical decision-making: Rethinking liability

Artificial Intelligence for Clinical Decision-Making: Gross Negligence Manslaughter and Corporate Manslaughter

Regulating Artificial Intelligence and Machine Learning-Enabled Medical Devices in Europe and the United Kingdom

Accidental injustice: Healthcare AI legal responsibility must be prospectively planned prior to its adoption

A study on civil liability of Artificial Intelligence

Clinical AI: opacity, accountability, responsibility and liability

Product liability for defective AI

Shepard’s Validation of Antitrust Relief Framework on Patent Infringement of Novartis’ Cancer Drug Using Genomic Architectures of Legal Literature Based on UK Intellectual Property Law

A foggy minefield: Experiences of regulation among developers of AI and other medical software in the UK, survey and focus group study

A risk-based approach to assessing liability risk for AI-driven harms considering EU liability directive

Learning From Experience and Finding the Right Balance in the Governance of Artificial Intelligence and Digital Health Technologies

Regulating algorithmic care in the European Union: evolving doctor–patient models through the Artificial Intelligence Act (AI-Act) and the liability directives

Regulating algorithmic care in the European Union: evolving doctor-patient models through the Artificial Intelligence Act (AI-Act) and the liability directives

Evaluating if Ghana's Health Institutions and Facilities Act 2011 (Act 829) Sufficiently Addresses Medical Negligence Risks from Integration of Artificial Intelligence Systems

How AI challenges the medical device regulation: patient safety, benefits, and intended uses

Artificial intelligence in medical device software and high-risk medical devices – a review of definitions, expert recommendations and regulatory initiatives

Fault–Based Liability for Medical Malpractice in the Age of Artificial Intelligence: Α Comparative Analysis of German and Greek Medical Liability Law in View of the Challenges Posed by AI Systems

The Risk-Based Approach of the European Union’s Proposed Artificial Intelligence Regulation: Some Comments from a Tort Law Perspective

Defining medical liability when artificial intelligence is applied on diagnostic algorithms: a systematic review

Implementing the human right to science in the regulatory governance of artificial intelligence in healthcare